Compare CASH & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | COLL |
|---|---|---|
| Founded | 1954 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.2B |
| IPO Year | 1996 | 2015 |
| Metric | CASH | COLL |
|---|---|---|
| Price | $91.05 | $35.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $96.33 | $50.83 |
| AVG Volume (30 Days) | 221.5K | ★ 419.5K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ 18.88 | N/A |
| EPS | 1.57 | ★ 1.73 |
| Revenue | ★ $839,894,000.00 | $780,567,000.00 |
| Revenue This Year | $7.56 | $6.07 |
| Revenue Next Year | $6.02 | N/A |
| P/E Ratio | $57.89 | ★ $20.65 |
| Revenue Growth | 11.29 | ★ 23.62 |
| 52 Week Low | $64.45 | $23.23 |
| 52 Week High | $96.06 | $50.79 |
| Indicator | CASH | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 26.84 |
| Support Level | $87.09 | $34.30 |
| Resistance Level | $95.58 | $36.20 |
| Average True Range (ATR) | 2.79 | 1.62 |
| MACD | -0.53 | -0.39 |
| Stochastic Oscillator | 48.26 | 14.72 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.